Evaluation of the Safety and Efficacy of Standard Dose Gemcitabine Combined With High Dose Intravenous Vitamin C (HDIVC) Treatment for Patients With Metastatic Adenocarcinoma of the Pancreas.

Trial Profile

Evaluation of the Safety and Efficacy of Standard Dose Gemcitabine Combined With High Dose Intravenous Vitamin C (HDIVC) Treatment for Patients With Metastatic Adenocarcinoma of the Pancreas.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Ascorbic acid (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 29 Apr 2016 Status changed from completed to discontinued because recruiting or enrolling participants has halted prematurely and will not resume.
    • 18 Dec 2015 Status changed from discontinued to completed as per ClinicalTrials.gov record.
    • 10 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top